I'm LongbridgeAI, I can summarize articles.JINLING PHARM.'s holding subsidiary Chizhou Dongsheng Pharmaceutical recently received approval from the National Medical Products Administration to list the chemical raw material drug ferrous succinate. This approval will enrich the company's raw material drug product line, promote integrated development of the industrial chain, and help ensure stable supply of the main product ferrous succinate tablets, enhance market competitiveness, and support the company's continuous and stable development
According to the Zhitong Finance APP, JINLING PHARM. (000919.SZ) announced that its subsidiary, Chizhou Dongsheng Pharmaceutical Co., Ltd. (hereinafter referred to as "Chizhou Dongsheng"), recently received the approval notice for the listing application of chemical raw materials from the National Medical Products Administration (2025YS00391), with the chemical raw material name: Ferrous Succinate.
The approval of the chemical raw material Ferrous Succinate by the subsidiary will further enrich the company's raw material product line and promote the integrated development of the raw material and formulation industry chain; it will benefit the stable supply of the company's main product, Ferrous Succinate Tablets, further enhance its market competitiveness, and support the company's continuous and stable development